Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiora Pharmaceuticals (KPRX) Total Non-Current Liabilities (2016 - 2025)

Kiora Pharmaceuticals' Total Non-Current Liabilities history spans 11 years, with the latest figure at $4.5 million for Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities fell 4.68% year-over-year to $4.5 million; the TTM value through Dec 2025 reached $4.5 million, down 4.68%, while the annual FY2025 figure was $4.5 million, 4.68% down from the prior year.
  • Total Non-Current Liabilities reached $4.5 million in Q4 2025 per KPRX's latest filing, down from $4.9 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $6.6 million in Q2 2025 to a low of $3.8 million in Q2 2022.
  • Average Total Non-Current Liabilities over 5 years is $5.1 million, with a median of $5.0 million recorded in 2024.
  • Peak YoY movement for Total Non-Current Liabilities: skyrocketed 213.68% in 2021, then tumbled 40.75% in 2022.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $3.9 million in 2021, then rose by 5.2% to $4.1 million in 2022, then soared by 43.93% to $6.0 million in 2023, then dropped by 20.98% to $4.7 million in 2024, then dropped by 4.68% to $4.5 million in 2025.
  • Per Business Quant, the three most recent readings for KPRX's Total Non-Current Liabilities are $4.5 million (Q4 2025), $4.9 million (Q3 2025), and $6.6 million (Q2 2025).